DOCSLIB.ORG

Auspar Attachment 2: Extract from the Clinical Evaluation Report For

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Auspar Attachment 2: Extract from the Clinical Evaluation Report For AusPAR Attachment 2 Extract from the Clinical Evaluation Report for Arsenic trioxide Proprietary Product Name: Phenasen Sponsor: Phebra Pty Ltd First Round CER report: 19 November 2014 Therapeutic Goods Administration About the Therapeutic Goods Administration (TGA) · The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health, and is responsible for regulating medicines and medical devices. · The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance), when necessary. · The work of the TGA is based on applying scientific and clinical expertise to decision- making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. · The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. · To report a problem with a medicine or medical device, please see the information on the TGA website <https://www.tga.gov.au>. About the Extract from the Clinical Evaluation Report · This document provides a more detailed evaluation of the clinical findings, extracted from the Clinical Evaluation Report (CER) prepared by the TGA. This extract does not include sections from the CER regarding product documentation or post market activities. · The words [Information redacted], where they appear in this document, indicate that confidential information has been deleted. · For the most recent Product Information (PI), please refer to the TGA website <https://www.tga.gov.au/product-information-pi>. Copyright © Commonwealth of Australia 2015 This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the TGA Copyright Officer, Therapeutic Goods Administration, PO Box 100, Woden ACT 2606 or emailed to <[email protected]>. Submission PM-2014-02385-1-4 Extract from the Clinical Evaluation Report for Arsenic trioxide Page 2 of 104 Phenasen Therapeutic Goods Administration Contents List of abbreviations __________________________________________________________ 5 1. Introduction _______________________________________________________________ 8 1.1. Submission type _____________________________________________________________ 8 1.2. Drug class and therapeutic indication _____________________________________ 8 1.3. Dosage forms and strengths ________________________________________________ 8 1.4. Dosage and administration _________________________________________________ 8 2. Clinical rationale _________________________________________________________ 9 3. Contents of the clinical dossier ______________________________________ 10 3.1. Scope of the clinical dossier _______________________________________________ 10 3.2. Paediatric data _____________________________________________________________ 12 3.3. Good clinical practice ______________________________________________________ 13 4. Pharmacokinetics ______________________________________________________ 13 4.1. Studies providing pharmacokinetic data ________________________________ 13 5. Pharmacodynamics ____________________________________________________ 13 5.1. Studies providing pharmacodynamic data ______________________________ 13 6. Dosage selection for the pivotal studies ___________________________ 13 7. Clinical efficacy _________________________________________________________ 13 7.1. For extended indication ___________________________________________________ 13 8. Clinical safety ___________________________________________________________ 69 8.1. Studies providing evaluable safety data _________________________________ 69 8.2. Pivotal studies that assessed safety as a primary outcome ____________ 70 8.3. Patient exposure ___________________________________________________________ 70 8.4. Safety results in the combination treatment studies____________________ 73 8.5. Safety results in the published single agent studies ____________________ 85 8.6. Post-marketing experience _______________________________________________ 89 8.7. Safety issues with the potential for major regulatory impact __________ 90 8.8. Other safety issues _________________________________________________________ 90 8.9. Evaluator’s overall conclusions on clinical safety _______________________ 92 9. First round benefit-risk assessment ________________________________ 96 9.1. First round assessment of benefits _______________________________________ 96 9.2. First round assessment of risks __________________________________________ 97 9.3. First round assessment of benefit-risk balance _________________________ 97 10. First round recommendation regarding authorisation _______ 99 11. Clinical questions ____________________________________________________ 99 Submission PM-2014-02385-1-4 Extract from the Clinical Evaluation Report for Arsenic trioxide Page 3 of 104 Phenasen Therapeutic Goods Administration 11.1. Pharmacokinetics __________________________________________________________ 99 11.2. Pharmacodynamics ________________________________________________________ 99 11.3. Efficacy ____________________________________________________________________ 100 11.4. Safety ______________________________________________________________________ 100 12. Second round evaluation of clinical data submitted in response to questions _____________________________________________________________________ 101 13. References ___________________________________________________________ 101 Submission PM-2014-02385-1-4 Extract from the Clinical Evaluation Report for Arsenic trioxide Page 4 of 104 Phenasen Therapeutic Goods Administration List of abbreviations Abbreviation Meaning 6MP 6-mercaptopurine ADR Adverse drug reaction AE Adverse event AIDA all trans retinoic and idarubicin ALLG Australasian Leukaemia and Lymphoma Group ALT Alanine amino transferase AML Acute myelogenous leukemia APL Acute promyelocytic leukaemia (also APML) APLDS APL differentiation syndrome APML3,APML4 ALLG APML trial codes, 3rd and 4th trials AST Aspartate amino transferase ATO Arsenic trioxide, As2O3 ATRA All-trans retinoic acid BaCT Centre for Biostatistics and Clinical Trials CI Confidence interval CNS Central nervous system CR Complete remission CSR Clinical study report CT chemotherapy CTCAE Common terminology criteria for adverse events D Daunorubicin DFS Disease free survival DMSC Data Management and Safety Committee EC Ethics committee Submission PM-2014-02385-1-4 Extract from the Clinical Evaluation Report for Arsenic trioxide Page 5 of 104 Phenasen Therapeutic Goods Administration Abbreviation Meaning ECG Electrocardiogram EFS Event-free survival FAB French-American-British, classification system FFS Failure Free Survival FLT3 FMS-like tyrosine kinase-3 GCP Good clinical practices GGT Gamma glutamine transferase GI Gastrointestinal H Homoharringtinone HCR Haematological complete remission IDA Idarubicin ITT Intention-to-treat iv Intravenous mRNA Messenger ribonucleic acid MTX Methotrexate NCCN National Comprehensive Cancer Network NCI National Cancer Institute ND Not done OS Overall survival PML- Promyelocytic leukaemia – retinoic acid receptor alpha fusion gene PP RARα Per protocol QTc QT interval RCT Randomised controlled trial RFS Relapse free survival RT-PCR Reverse transcriptase-polymerase chain reaction Submission PM-2014-02385-1-4 Extract from the Clinical Evaluation Report for Arsenic trioxide Page 6 of 104 Phenasen Therapeutic Goods Administration Abbreviation Meaning SAE Serious adverse event TE Thromboembolism TGA Therapeutic Goods Administration TTR Time to relapse VZV Varicella Zoster Virus WBC White blood count WCC White cell count Submission PM-2014-02385-1-4 Extract from the Clinical Evaluation Report for Arsenic trioxide Page 7 of 104 Phenasen Therapeutic Goods Administration 1. Introduction 1.1. Submission type This is a Category 1 Type-C submission for extension of indications. 1.2. Drug class and therapeutic indication Phenasen (ATO) is an antineoplastic agent (ATC code L01XX27: Antineoplastic and immunomodulating agents – Other antineoplastic agents). The approved indication is: ‘For the induction of remission and consolidation in patients with acute promyelocytic leukaemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterised by the presence of the t(15:17) translocation or PML/RAR-alpha gene expression.’ The proposed {additional/replacement} indication is: ‘For the induction of remission and consolidation in patients with previously untreated Acute promyelocytic leukaemia (APL) in combination with all-trans retinoic acid (ATRA) and chemotherapy
Load more

Recommended publications
  • Transcatheter Arterial Chemoembolization Therapy for Hepatocellular Carcinoma Using Polylactic Acid Microspheres Containing Acla
    [CANCER RESEARCH 49. 4357-4362, August 1. 1989] Transcatheter Arterial Chemoembolization Therapy for Hepatocellular Carcinoma Using Polylactic Acid Microspheres Containing Aclarubicin Hydrochloride 1omonimi Ichihara,1 Kiyoshi Sakamoto, Katsutaka Mori, and Masanobu Akagi Department of Surgery II, Kumamoto University Medical School, Kumamoto 860, Japan 4BSTRACT MATERIALS AND METHODS Transcatheter arterial Chemoembolization therapy using polylactic Preparation of PLA-ACRms acid microspheres containing aclarubicin hydrochloride (ACR) was per PLA-ACRms were prepared in the pharmacy of the Kumamoto formed in 62 patients with primary hepatocellular carcinoma. These microspheres were about 200 ¡anin diameter and contained 10% (w/w) University Hospital. Briefly, aclarubicin hydrochloride and isopropyl aclarubicin. A single dose of polylactic acid microspheres containing ACR myristate, a medium-chain fatty acid ester, were dissolved in 7.5% (50-100 mg of ACR) was administered 1 to 8 times with a mean of 2.2 polylactic acid-methylene chloride. The resultant solution was dispersed in 1% gelatin solution and sterilized in an autoclave for 20 min at doses (a total of 160 treatments) in 62 patients. Antitumor effects were 120°C;thismixture was then stirred with a magnetic stirrer at 500 rpm observed from the decrease in serum a-fetoprotein levels (82.1% of the patients) and in two dimensional size of tumor on computed tomography for 1 h. The resultant microspheres were collected by filtration through (93.6%). The cumulative survival rate was 54.3% at 1 year, 24.6% at 2 a membrane filter (3 //m pore diameter), rinsed 2 to 3 times (in 1 liter years, and 19.2% at 3 years, respectively, among 59 patients with of distilled water), and dried under reduced pressure for 5 days.
    [Show full text]
  • Arsenic Summary & Details: Greenfacts
    http://www.greenfacts.org/ Copyright © GreenFacts page 1/9 Scientific Facts on Source document: IPCS (2001) Arsenic Summary & Details: GreenFacts Level 2 - Details on Arsenic 1. What is arsenic?.............................................................................................................3 1.1 What are the properties of arsenic?...................................................................................3 1.2 How are arsenic levels measured?.....................................................................................3 2. Where does environmental arsenic come from?....................................................3 2.1 What are the natural sources of environmental arsenic?.......................................................3 2.2 What are the man-made sources of environmental arsenic?..................................................4 2.3 How is arsenic transported and distributed in the environment?............................................4 3. What are the levels of exposure to arsenic?...........................................................4 3.1 How much arsenic is there in the environment?..................................................................4 3.2 What levels of arsenic are found in living organisms?...........................................................5 3.3 What levels of arsenic are humans exposed to?..................................................................5 4. What happens to arsenic in the body?......................................................................6 4.1
    [Show full text]
  • Phenotype Microarrays Panels PM-M1 to PM-M14
    Phenotype MicroArrays™ Panels PM-M1 to PM-M14 for Phenotypic Characterization of Mammalian Cells Assays: Energy Metabolism Pathways Ion and Hormone Effects on Cells Sensitivity to Anti-Cancer Agents and for Optimizing Culture Conditions for Mammalian Cells PRODUCT DESCRIPTIONS AND INSTRUCTIONS FOR USE PM-M1 Cat. #13101 PM-M2 Cat. #13102 PM-M3 Cat. #13103 PM-M4 Cat. #13104 PM-M5 Cat. #13105 PM-M6 Cat. #13106 PM-M7 Cat. #13107 PM-M8 Cat. #13108 PM-M11 Cat. #13111 PM-M12 Cat. #13112 PM-M13 Cat. #13113 PM-M14 Cat. #13114 © 2016 Biolog, Inc. All rights reserved Printed in the United States of America 00P 134 Rev F February 2020 - 1 - CONTENTS I. Introduction ...................................................................................................... 2 a. Overview ................................................................................................... 2 b. Background ............................................................................................... 2 c. Uses ........................................................................................................... 2 d. Advantages ................................................................................................ 3 II. Product Description, PM-M1 to M4 ................................................................ 3 III. Protocols, PM-M1 to M4 ................................................................................. 7 a. Materials Required .................................................................................... 7 b. Determination
    [Show full text]
  • Arsenic Trioxide Is Highly Cytotoxic to Small Cell Lung Carcinoma Cells
    160 Arsenic trioxide is highly cytotoxic to small cell lung carcinoma cells 1 1 Helen M. Pettersson, Alexander Pietras, effect of As2O3 on SCLC growth, as suggested by an Matilda Munksgaard Persson,1 Jenny Karlsson,1 increase in neuroendocrine markers in cultured cells. [Mol Leif Johansson,2 Maria C. Shoshan,3 Cancer Ther 2009;8(1):160–70] and Sven Pa˚hlman1 1Center for Molecular Pathology, CREATE Health and 2Division of Introduction Pathology, Department of Laboratory Medicine, Lund University, 3 Lung cancer is the most frequent cause of cancer deaths University Hospital MAS, Malmo¨, Sweden; and Department of f Oncology-Pathology, Cancer Center Karolinska, Karolinska worldwide and results in 1 million deaths each year (1). Institute and Hospital, Stockholm, Sweden Despite novel treatment strategies, the 5-year survival rate of lung cancer patients is only f15%. Small cell lung carcinoma (SCLC) accounts for 15% to 20% of all lung Abstract cancers diagnosed and is a very aggressive malignancy Small cell lung carcinoma (SCLC) is an extremely with early metastatic spread (2). Despite an initially high aggressive form of cancer and current treatment protocols rate of response to chemotherapy, which currently com- are insufficient. SCLC have neuroendocrine characteristics bines a platinum-based drug with another cytotoxic drug and show phenotypical similarities to the childhood tumor (3, 4), relapses occur in the absolute majority of SCLC neuroblastoma. As multidrug-resistant neuroblastoma patients. At relapse, the efficacy of further chemotherapy is cells are highly sensitive to arsenic trioxide (As2O3) poor and the need for alternative treatments is obvious. in vitro and in vivo, we here studied the cytotoxic effects Arsenic-containing compounds have been used in tradi- of As2O3 on SCLC cells.
    [Show full text]
  • Arsenic Trioxide
    Arsenic trioxide DRUG NAME: Arsenic trioxide 1 SYNONYM(S): arsenic, As2O3, white arsenic COMMON TRADE NAME(S): TRISENOX® CLASSIFICATION: miscellaneous Special pediatric considerations are noted when applicable, otherwise adult provisions apply. MECHANISM OF ACTION: Arsenic is an element classed as a semi-metal or metalloid and it exists as chemically unstable oxides and sulfides as well as arsenites or arsenates of sodium, calcium, and potassium. Arsenic trioxide is an inorganic form of arsenic and is the most widely studied arsenical-based cancer drug.1 Although its mechanism is not completely understood, arsenic trioxide may have a multi-modal mechanism of action likely dependent on dose. At lower doses, arsenic trioxide promotes partial cellular differentiation, while at higher doses it leads to morphological changes and DNA fragmentation characteristic of apoptosis. Other key effects include damage or degradation of the fusion protein PML-RARα and inhibition of growth and angiogenesis. Arsenic trioxide also reduces procoagulant activity and tissue factor gene expression. It demonstrates antivasculogenic activity in tumour xenografts and enhances the sensitivity of neoplastic cell lines and tumour xenografts to radiation therapy.2 PHARMACOKINETICS: Absorption arsenious acid (primary pharmacologically active form) formed immediately by hydrolysis in solution Distribution rapid distribution to highly perfused organs; arsenic accumulates in liver, kidney, heart, and to a lesser extent in lung, hair, and nails; no evidence of distribution
    [Show full text]
  • Arsenic Trioxide Targets MTHFD1 and SUMO-Dependent Nuclear De Novo Thymidylate Biosynthesis
    Arsenic trioxide targets MTHFD1 and SUMO-dependent PNAS PLUS nuclear de novo thymidylate biosynthesis Elena Kamyninaa, Erica R. Lachenauera,b, Aislyn C. DiRisioa, Rebecca P. Liebenthala, Martha S. Fielda, and Patrick J. Stovera,b,c,1 aDivision of Nutritional Sciences, Cornell University, Ithaca, NY 14853; bGraduate Field of Biology and Biomedical Sciences, Cornell University, Ithaca, NY 14853; and cGraduate Field of Biochemistry, Molecular and Cell Biology, Cornell University, Ithaca, NY 14853 Contributed by Patrick J. Stover, February 12, 2017 (sent for review December 1, 2016; reviewed by I. David Goldman and Anne Parle-McDermott) Arsenic exposure increases risk for cancers and is teratogenic in levels. Decreased rates of de novo dTMP synthesis can be caused animal models. Here we demonstrate that small ubiquitin-like by the action of chemotherapeutic drugs (19), through inborn modifier (SUMO)- and folate-dependent nuclear de novo thymidylate errors of folate transport and metabolism (15, 18, 20, 21), by (dTMP) biosynthesis is a sensitive target of arsenic trioxide (As2O3), inhibiting translocation of the dTMP synthesis pathway enzymes leading to uracil misincorporation into DNA and genome instability. into the nucleus (2) and by dietary folate deficiency (22, 23). Im- Methylenetetrahydrofolate dehydrogenase 1 (MTHFD1) and serine paired dTMP synthesis leads to genome instability through well- hydroxymethyltransferase (SHMT) generate 5,10-methylenetetrahy- characterized mechanisms associated with uracil misincorporation drofolate for de novo dTMP biosynthesis and translocate to the nu- into nuclear DNA and subsequent futile cycles of DNA repair (24, cleus during S-phase, where they form a multienzyme complex with 25). Nuclear DNA is surveyed for the presence of uracil by a thymidylate synthase (TYMS) and dihydrofolate reductase (DHFR), as family of uracil glycosylases including: uracil N-glycolase (UNG), well as the components of the DNA replication machinery.
    [Show full text]
  • Towards the Reduction of Occupational Exposure To
    TOWARDS THE REDUCTION OF OCCUPATIONAL EXPOSURE TO CYTOTOXIC DRUGS by Cristian Vasile Barzan B.Sc. Simon Fraser University, 2007 A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIRMENTS FOR THE DEGREE OF MASTER OF SCIENCE in The Faculty of Graduate Studies (Occupational and Environmental Hygiene) THE UNIVERSITY OF BRITISH COLUMBIA (Vancouver) October 2010 © Cristian Vasile Barzan, 2010 Abstract Background : One of the most powerful and widely used techniques in cancer treatment is the use of cytotoxic drugs in chemotherapy. These drugs are inherently hazardous with many of them causing carcinogenic, mutagenic or teratogenic health outcomes. Occupational exposure to cytotoxic drugs is of great concern due to their lack of selectivity between healthy and unhealthy cells. Widespread cytotoxic drug contamination has been reported in North America, Europe and Australia. Current cleaning protocols for hazardous antineoplastic drugs include the use of disinfectants and oxidizing agents, such as household bleach. Aim : The thesis project focused on two objectives: 1) hypothesize and confirm potential hazardous by- products arising from cleaning cyclophosphamide, a widely used cytotoxic drugs, with household bleach, a commonly used cleaning agent; 2) develop an effective and safe cleaning agent for cytotoxic drugs in order to prevent and eliminate exposure to these drugs. Methods : The gas chromatograph mass spectrum (GC/MS) was used to analyze the decomposition of cyclophosphamide by household bleach (5.25% hypochlorite). The reaction was conducted in a test-tube and the by-products extracted and derivatized prior to analysis. Multiple cleaning agent compositions were tested on 10x10cm stainless steel plates spiked with the two model cytotoxic drugs, cyclophosphamide and methotrexate.
    [Show full text]
  • Functional Similarity of Anticancer Drugs by MTT Bioassay
    cer Scien an ce C & f o T l h a e Hiwasa et al., J Cancer Sci Ther 2011, 3.10 n r a Journal of r p u 1000099 y o J DOI: 10.4172/1948-5956. ISSN: 1948-5956 Cancer Science & Therapy Rapid Communication Open Access Functional Similarity of Anticancer Drugs by MTT Bioassay Takaki Hiwasa1*,Takanobu Utsumi1, Mari Yasuraoka1, Nana Hanamura1, Hideaki Shimada2, Hiroshi Nakajima3, Motoo Kitagawa4, Yasuo Iwadate4,5, Ken-ichiro Goto6, Atsushi Takeda7, Kenzo Ohtsuka8, Hiroyoshi Ariga9 and Masaki Takiguchi1 1Department of Biochemistry, and Genetics, Chiba University, Graduate School of Medicine, Chuo-ku, Chiba 260-8670, Japan 2Department of Surgery, School of Medicine, Toho University, Ota-ku, Tokyo 143-8541, Japan 3Department of Molecular Genetics, Chiba University, Graduate School of Medicine, Chuo-ku, Chiba 260-8670, Japan 4Department of Molecular and Tumor Pathology, Chiba University, Graduate School of Medicine, Chuo-ku, Chiba 260-8670, Japan 5Department of Neurological Surgery, Chiba University, Graduate School of Medicine, Chuo-ku, Chiba 260-8670, Japan 6Department of Orthopaedic Surgery, National Hospital Organization, Shimoshizu Hospital, Yotsukaido, Chiba 284-0003, Japan 7Laboratory of Biochemistry, Graduate School of Nutritional Sciences, Sagami Women’s University, Sagamihara, Kanagawa 252-0383, Japan 8Laboratory of Cell & Stress Biology, Department of Environmental Biology, Chubu University, Matsumoto-cho, Kasugai, Aichi 487-8501, Japan 9Graduate School of Pharmaceutical Sciences, Hokkaido University, Kita-ku, Sapporo 060-0812, Japan Abstract We prepared normal or Ha-ras-transformed NIH3T3 cells transfected stably or transiently with various tumor- related genes. The chemosensitivity of the transfected clones to 16 anticancer drugs was compared to the parental control cells using the MTT assay.
    [Show full text]
  • Characteristics of Doxorubicin‑Selected Multidrug‑Resistant Human Leukemia HL‑60 Cells with Tolerance to Arsenic Trioxide and Contribution of Leukemia Stem Cells
    ONCOLOGY LETTERS 15: 1255-1262, 2018 Characteristics of doxorubicin‑selected multidrug‑resistant human leukemia HL‑60 cells with tolerance to arsenic trioxide and contribution of leukemia stem cells JING CHEN, HULAI WEI, JIE CHENG, BEI XIE, BEI WANG, JUAN YI, BAOYING TIAN, ZHUAN LIU, FEIFEI WANG and ZHEWEN ZHANG Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences, Lanzhou University, Lanzhou, Gansu 730000, P.R. China Received December 29, 2015; Accepted June 9, 2017 DOI: 10.3892/ol.2017.7353 Abstract. The present study selected and characterized resistance (MDR) frequently induces therapy failure or tumor a multidrug-resistant HL-60 human acute promyelocytic recurrence (1-3). MDR involves various mechanisms including, leukemia cell line, HL-60/RS, by exposure to stepwise adenosine triphosphate-binding cassette (ABC) transporters, incremental doses of doxorubicin. The drug-resistant P-glycoprotein (P-gp), multidrug-resistance-related protein HL-60/RS cells exhibited 85.68-fold resistance to doxoru- (MRP) and breast-cancer-resistance protein (BCRP) overex- bicin and were cross-resistant to other chemotherapeutics, pression, which function to efflux certain molecules out of including cisplatin, daunorubicin, cytarabine, vincristine the cells (4-8). In addition, mechanisms of acquired MDR and etoposide. The cells over-expressed the transporters in leukemia also include abnormal drug metabolism and the P-glycoprotein, multidrug-resistance-related protein 1 presence of leukemia stem cells (LSC). LSCs are particu- and breast-cancer-resistance protein, encoded by the larly of interest and considered to serve an important role adenosine triphosphate-binding cassette (ABC)B1, ABCC1 in leukemia resistance and relapse (4).
    [Show full text]
  • Metabolic Carbonyl Reduction of Anthracyclines — Role in Cardiotoxicity and Cancer Resistance
    Invest New Drugs DOI 10.1007/s10637-017-0443-2 REVIEW Metabolic carbonyl reduction of anthracyclines — role in cardiotoxicity and cancer resistance. Reducing enzymes as putative targets for novel cardioprotective and chemosensitizing agents Kamil Piska1 & Paulina Koczurkiewicz1 & Adam Bucki 2 & Katarzyna Wójcik-Pszczoła1 & Marcin Kołaczkowski2 & Elżbieta Pękala1 Received: 23 November 2016 /Accepted: 17 February 2017 # The Author(s) 2017. This article is published with open access at Springerlink.com Summary Anthracycline antibiotics (ANT), such as doxoru- monoHER, curcumin, (−)-epigallocatechin gallate, resvera- bicin or daunorubicin, are a class of anticancer drugs that are trol, berberine or pixantrone, and their modulating effect on widely used in oncology. Although highly effective in cancer the activity of ANT is characterized and discussed as potential therapy, their usefulness is greatly limited by their mechanism of action for novel therapeutics in cancer cardiotoxicity. Possible mechanisms of ANT cardiotoxicity treatment. include their conversion to secondary alcohol metabolites (i.e. doxorubicinol, daunorubicinol) catalyzed by carbonyl re- Keywords Anthracyclines . Cardiotoxicity . Resistance . ductases (CBR) and aldo-keto reductases (AKR). These me- Pharmacokinetics . Drug metabolism . Anticancer agents tabolites are suspected to be more cardiotoxic than their parent compounds. Moreover, overexpression of ANT-reducing en- zymes (CBR and AKR) are found in many ANT-resistant Introduction cancers. The secondary metabolites show decreased cytotoxic properties and are more susceptible to ABC-mediated efflux Anthracyclines (ANT) are a class of cell-cycle non-specific than their parent compounds; thus, metabolite formation is anticancer antibiotics that were first isolated from the considered one of the mechanisms of cancer resistance. Streptomyces genus in the early 1960s.
    [Show full text]
  • Inorganic Arsenic Compounds Other Than Arsine Health and Safety Guide
    OS INTERNATiONAL I'ROGRAMME ON CHEMICAL SAFETY Health and Safety Guide No. 70 INORGANIC ARSENIC COMPOUNDS OTHER THAN ARSINE HEALTH AND SAFETY GUIDE i - I 04 R. Q) UNEP UNITED NATIONS INTERNATIONAL ENVIRONMENT I'R( )GRAMME LABOUR ORGANISATION k\s' I V WORLD HEALTH ORGANIZATION WORLD HEALTH ORGANIZATION, GENEVA 1992 IPcs Other H EA LTH AND SAFETY GUIDES available: Aerytonitrile 41. Clii rdeon 2. Kekvau 42. Vatiadiuni 3 . I Bula not 43 Di meLhyI ftirmatnide 4 2-Buta101 44 1-Dryliniot 5. 2.4- Diehlorpheiioxv- 45 . Ac rylzi mule acetic Acid (2.4-D) 46. Barium 6. NIcihylene Chhride 47. Airaziiie 7 . ie,i-Buia nol 48. Benlm'.ie 8. Ep Ichioroli) Olin 49. Cap a 64 P. ls.ihutaiiol 50. Captaii I o. feiddin oeth N lene Si. Parai.tuat II. Tetradi ion 51 Diquat 12. Te nacelle 53. Alpha- and Betal-lexachloro- 13 Clils,i (lane cyclohexanes 14 1 kpia Idor 54. Liiidaiic IS. Propylene oxide 55. 1 .2-Diciilroetiiane Ethylene Oxide 5t. Hydrazine Eiulosiillaii 57. F-orivaldehydc IS. Die h lorvos 55. MLhyI Isobu I V I kcloiic IV. Pculaehloro1heiiol 59. fl-Flexaric 20. Diiiiethoaie 61), Endrin 2 1 . A iii in and Dick) 0in 6 I . I sh IIZiLI1 22. Cyperniellirin 62. Nicki. Nickel Caution I. and some 23. Quiiiloieiic Nickel Compounds 24. Alkthrins 03. Hexachlorocyclopeuladiene 25. Rsiiiethii ins 64. Aidicaib 26. Pyr rot ii,id inc Alkaloids 65. Fe nitrolhioit 27. Magnetic Fields hib. Triclilorlon 28. Phosphine 67. Acroleiii 29. Diiiiethyl Sull'ite 68. Polychlurinated hiphenyls (PCBs) and 30. Dc lianteth nil polyc h In ruiated letlilienyls (fs) 31.
    [Show full text]
  • Arsenic Trioxide (Trisenox®) (“AR Se Nik Trye OX Ide”)
    Arsenic Trioxide (Trisenox®) (“AR se nik trye OX ide”) How drug is given: By vein (intravenously, IV) Purpose: THis medication is used in the treatment of acute promyelocytic leukemia Things that may occur during or within hours of treatment 1. Facial flusHing (warmtH or redness of tHe face), itcHing, or a skin rasH could occur. THese symptoms are due to an allergic response and you should report them to your doctor or nurse right away. 2. Some patients may feel very tired, also known as fatigue. You may need to rest or take naps more often. Mild to moderate exercise may also help you maintain your energy. 3. Mild to moderate nausea, vomiting, and loss of appetite may occur. You may be given medicine to help with this. Things that may occur a few days to weeks later 1. Your body may not be able to get rid of extra fluid. This is called edema. You may notice some swelling in your arms or legs. 2. If you have an ongoing fever of 100.5°F (38°C) or higher, call your doctor or nurse right away. Make sure you are drinking plenty of fluids. 3. This drug may affect your heart. Your heart function will be followed with a weekly EKG. You may have a fast or unusual heartbeat. If you feel any strange changes in your heartbeat, tell your doctor or nurse right away. You should also let your doctor or nurse know if you are cougHing, Having trouble breatHing, Have cHest pain and/or swelling in tHe feet or ankles.
    [Show full text]